Global Ophthalmic Drugs Market Forecast 2017-2024
KEY FINDINGS
The global ophthalmic drugs and device market is expected to grow at a CAGR of 5.78% during 2017-2025 and is estimated to reach $87343.53 million by 2025. In 2016, the global ophthalmic drugs and devices market was valued at $52866 million. The rising eye related disorders in the world, changing lifestyle, and rising healthcare expenditure are the major driving factors in the growth of the global ophthalmic drug and devices market.
MARKET INSIGHTS
The ophthalmic drugs & devices market is segmented into various diagnostic and monitoring equipment, surgical devices, and vision care products. All such categorization being furthermore divided into device types, technology and features of the devices. Well-known drugs are going off patent and key players affected by the delay in new drugs coming into the market are the two factors restricting the growth of the market. The market faces challenges in risk associated with the ocular diseases and lack of awareness among people regarding ophthalmology.
REGIONAL INSIGHTS
Geographically global ophthalmic drugs & devices market is segmented into North America, Europe, Asia-Pacific, and Rest of World. Currently, North America holds a massive market share followed by Europe and Asia-Pacific. Due to rising geriatric population, increase in strategic initiatives by large market players present in the region and increasing prevalence of ocular diseases, the North America ophthalmic drugs & devices market holds high growth prospects in the near futureHowever, over the forecasted period Asia-Pacific is expected to grow at the highest CAGR. APAC market is majorly driven by the rising prevalence and increasing facilities for eye treatment in hospitals.
COMPETITIVE INSIGHTS
On the basis of devices, this market is dominated by global players like Alex and Topcon Corporation.Global ophthalmic drugs market has a large number of market players but, the market is dominated by companies like Novartis AG and Santen.
The global ophthalmic drugs and device market is expected to grow at a CAGR of 5.78% during 2017-2025 and is estimated to reach $87343.53 million by 2025. In 2016, the global ophthalmic drugs and devices market was valued at $52866 million. The rising eye related disorders in the world, changing lifestyle, and rising healthcare expenditure are the major driving factors in the growth of the global ophthalmic drug and devices market.
MARKET INSIGHTS
The ophthalmic drugs & devices market is segmented into various diagnostic and monitoring equipment, surgical devices, and vision care products. All such categorization being furthermore divided into device types, technology and features of the devices. Well-known drugs are going off patent and key players affected by the delay in new drugs coming into the market are the two factors restricting the growth of the market. The market faces challenges in risk associated with the ocular diseases and lack of awareness among people regarding ophthalmology.
REGIONAL INSIGHTS
Geographically global ophthalmic drugs & devices market is segmented into North America, Europe, Asia-Pacific, and Rest of World. Currently, North America holds a massive market share followed by Europe and Asia-Pacific. Due to rising geriatric population, increase in strategic initiatives by large market players present in the region and increasing prevalence of ocular diseases, the North America ophthalmic drugs & devices market holds high growth prospects in the near futureHowever, over the forecasted period Asia-Pacific is expected to grow at the highest CAGR. APAC market is majorly driven by the rising prevalence and increasing facilities for eye treatment in hospitals.
COMPETITIVE INSIGHTS
On the basis of devices, this market is dominated by global players like Alex and Topcon Corporation.Global ophthalmic drugs market has a large number of market players but, the market is dominated by companies like Novartis AG and Santen.
1 RESEARCH SCOPE
1.1 STUDY GOALS
1.2 SCOPE OF MARKET STUDY
1.3 WHO WILL FIND THIS REPORT USEFUL?
1.4 STUDY AND FORECASTING YEARS
2 RESEARCH METHODOLOGY
2.1 SOURCES OF DATA
2.1.1 SECONDARY DATA
2.1.2 PRIMARY DATA
2.2 TOP DOWN APPROACH
2.3 BOTTOM-UP APPROACH
2.4 DATA TRIANGULATION
3 EXECUTIVE SUMMARY
3.1 KEY FINDINGS
4 MARKET OVERVIEW
4.1 MARKET DEFINITION AND SCOPE
4.2 TOP OPHTHALMIC DRUG BRANDS
5 MARKET DETERMINANTS
5.1 MARKET DRIVERS
5.1.1 INCREASING FDA APPROVALS GIVING A BOOST TO ADOPTION OF DRUGS AND DEVICES
5.1.2 SURGERIES IN OPHTHALMOLOGY MARKET ON RISE DUE TO HIGH PREVALENCE RATE OF REFRACTIVE ERRORS
5.1.3 INCREASING GERIATRIC POPULATION GLOBALLY
5.1.4 RISING PREVALENCE OF EYE DISORDERS
5.1.5 INCREASED HEALTHCARE EXPENDITURE
5.1.6 MINIMALLY INVASIVE SURGERIES ADOPTION ON RISE
5.2 MARKET RESTRAINTS
5.2.1 RENOWNED DRUGS GOING OFF PATENT
5.2.2 MAJOR PLAYERS AFFECTED BY DRYING PIPELINES
5.3 MARKET OPPORTUNITIES
5.3.1 GROWING OPPORTUNITIES IN DEVELOPING ECONOMIES
5.3.2 EMERGING MARKETS PRESENT REMARKABLE GROWTH OPPORTUNITIES
5.4 MARKET CHALLENGES
5.4.1 RISK ASSOCIATED WITH THE OCULAR DISEASES
5.4.2 LACK OF AWARENESS
6 MARKET SEGMENTATION
6.1 BY OPHTHALMIC DEVICES
6.1.1 DIAGNOSTIC & MONITORING EQUIPMENT
6.1.1.1 OPTICAL COHERENCE TOMOGRAPHY SCANNERS
6.1.1.2 OPHTHALMIC ULTRA SOUND IMAGING SYSTEMS
6.1.1.3 FUNDUS CAMERA
6.1.1.4 OPHTHALMOSCOPES
6.1.1.5 RETINOSCOPE
6.1.1.6 PACHYMETER
6.1.1.7 WAVEFRONT ABERROMETERS
6.1.1.8 PERIMETERS/VISUAL FIELD ANALYZER
6.1.1.9 AUTOREFRACTORS/PHOROPTER
6.1.1.10 KERATOMETERS
6.1.1.11 SPECULAR MICROSCOPE
6.1.1.12 CORNEAL TOPOGHAPHERS
6.1.1.13 TONOMETERS
6.1.1.14 SLIT LAMPS
6.1.1.15 BIOMETERS
6.1.1.16 OTHER
6.1.2 SURGERY DEVICE
6.1.2.1 CATARACT SURGERY DEVICE
6.1.2.1.1 INTRAOCULAR LENS
6.1.2.1.2 PHACOEMULSIFICATION DEVICES
6.1.2.1.3 OPHTHALMIC VISCOELASTIC DEVICES
6.1.2.2 GLAUCOMA SURGERY DEVICE
6.1.2.2.1 STENTS AND IMPLANT
6.1.2.2.2 GLAUCOMA DRAINAGE DEVICE
6.1.2.2.3 GLAUCOMA SYSTEM
6.1.2.2.4 GLAUCOMA LASER
6.1.2.3 REFRACTIVE SURGERY DEVICE
6.1.2.3.1 EXCIMER LASER
6.1.2.3.2 EMCROKERATOME
6.1.2.3.3 FEMTOSECOND LASER
6.1.2.3.4 YAG LASER
6.1.2.4 VITREORETINAL SURGERY DEVICE
6.1.2.4.1 PHOTOCOAGULATION LASER
6.1.2.4.2 ILLUMINATION DEVICE
6.1.2.4.3 VITRECTOMY MACHINE
6.2 BY VISION CARE
6.2.1 CONTACT LENS
6.2.2 SPECTACLES
6.2.3 EYE EXAMS
6.3 BY OPHTHALMIC DRUGS
6.3.1 BY PRESCRIPTION TYPE
6.3.1.1 PRESCRIPTION BASED OPHTHALMIC DRUGS
6.3.1.2 OTC (OVER THE COUNTER DRUGS)
6.3.2 BY DRUG DELIVERY TYPES
6.3.2.1 EYE DROPS
6.3.2.2 CAPSULES & TABLET
6.3.2.3 EYE OINTMENT
6.3.2.4 EYE GEL
6.3.2.5 EYE SOLUTION
6.4 BY TYPE OF DISEASE
6.4.1 GLAUCOMA
6.4.1.1 XALATAN (LATANOPROST)/XALACOM (LATANOPROST AND TIMOLOL COMBINATION) (XALABRANDS)
6.4.1.2 LUMIGAN FRANCHISE [LUMIGAN (BIMATOPROST) + GANFORT (BIMATOPROST AND TIMOLOL COMBINATION)]
6.4.1.3 TAPROS/TAFLOTAN (TAFLUPROST)
6.4.1.4 SAFLUTAN/ZIOPTAN (TAFLUPROST)
6.4.1.5 ALPHAGAN (BRIMONIDINE)/COMBIGAN (BRIMONIDINE AND TIMOLOL COMBINATION)
6.4.1.6 COSOPT (DORZOLAMIDE AND TIMOLOL COMBINATION)/ TRUSOPT (DORZOLAMIDE)
6.4.1.7 AZARGA (BRINZOLAMIDE AND TIMOLOL COMBINATION)
6.4.1.8 AZOPT (BRINZOLAMIDE)
6.4.2 RETINAL DISORDER
6.4.2.1 LUCENTIS (RANIBIZUMAB)
6.4.2.2 VISUDYNE (VERTEPORFIN)
6.4.2.3 AVASTIN (BEVACIZUMAB)
6.4.2.4 EYLEA (AFLIBERCEPT)
6.4.3 DRY EYE DRUG
6.4.3.1 RESTASIS (CYCLOSPORINE)
6.4.3.2 HYALEIN (SODIUM HYALURONATE)
6.4.3.3 DIQUAS (DIQUAFOSOL SODIUM)
6.4.4 ALLERGIC CONJUNCTIVITIS, INFLAMMATION AND CONJUNCTIVITIS DRUGS
6.4.4.1 PATANOL/PATADAY/OPATANOL (OLOPATADINE)
6.4.4.2 BEPREVE (BEPOTASTINE BESILATE)
6.4.4.3 TOBRADEX (TOBRAMYCIN & DEXAMETHASONE COMBINATION)
6.4.4.4 XIBROM/BROMDAY (BROMFENAC)
6.4.4.5 VIGAMOX
6.4.4.6 AZASITE (AZITHROMYCIN)
6.5 BY THERAPEUTICS
6.5.1 DIABETIC MACULAR EDEMA
6.5.2 EYE CANCER
6.5.3 DIABETIC RETINOPATHY
6.5.4 RETINAL VEIN OCCLUSION
6.5.5 AGE-RELATED MACULAR DEGENERATION
6.5.6 CONJUNCTIVITIS
6.5.7 DRY EYE
6.5.8 GLAUCOMA
6.5.9 KERATITIS
6.5.10 GEOGRAPHIC ATROPHY
6.6 BY END USER
6.6.1 HOSPITALS
6.6.2 EYE CLINICS
6.6.3 DIAGNOSTIC CENTERS
6.6.4 PATIENTS
7 KEY ANALYTICS
7.1 PORTER’S FIVE FORCE ANALYSIS
7.1.1 BARGAINING POWER BUYERS
7.1.2 BARGAINING POWER OF SUPPLIER
7.1.3 THREATS OF NEW ENTARANTS
7.1.4 THREATS OF SUBSTITUTES
7.1.5 COMPETITIVE RIVALRY
7.2 VALUE CHAIN ANALYSIS
7.2.1 SUPPLIERS
7.2.2 MANUFACTURERS
7.2.3 DISTRIBUTORS AND RETAILERS
7.2.4 END USERS
7.3 KEY BUYING CRITERIA
7.4 KEY MARKET INSIGHTS
7.4.1 TOP 3 EMERGING COUNTRIES
7.4.2 TOP REVENUE GENERATING SEGMENTS
7.4.3 TOP GROWING MARKETS AND EMERGING TRENDS
7.4.4 R&D SCENARIO IN OPHTHALMOLOGY MARKET
7.4.4.1 PLASMA TECHNOLOGY IN OPHTHALMOLOGY
7.4.4.2 CORNIAL TOPOGRAPHY & CORNIAL ANALYSIS
7.4.4.3 SCOPE OF VIRTUAL REALITY TECHNOLOGY IN EYE CARE
7.5 SECTOR ANALYSIS
7.5.1 PARENT MARKET
7.5.2 SUB-SEGMENT MARKET
7.5.3 ALTERNATIVE MARKET
7.6 STRATEGIC RECOMMENDATION
7.7 STRATEGIC CONCLUSIONS
8 GEOGRAPHIC ANALYSIS
8.1 NORTH AMERICA
8.1.1 UNITED STATES (U.S.)
8.1.2 CANADA
8.2 EUROPE
8.2.1 UNITED KINGDOM (UK)
8.2.2 FRANCE
8.2.3 GERMANY
8.2.4 SPAIN
8.2.5 ITALY
8.2.6 REST OF EUROPE (ROE)
8.3 ASIA PACIFIC
8.3.1 INDIA
8.3.2 CHINA
8.3.3 JAPAN
8.3.4 SOUTH KOREA
8.3.5 AUSTRALIA
8.3.6 ROAPAC
8.4 REST OF THE WORLD
8.4.1 LATIN AMERICA
8.4.2 MIDDLE EAST & AFRICA
9 COMPETITIVE LANDSCAPE
9.1 MARKET SHARE ANALYSIS
9.2 TOP WINNING STRATEGIES
9.3 CASE STUDIES: TOP COMPETITIVE MOVES
9.4 COMPANY PROFILES
9.4.1 ABBOTT LABORATORIES
9.4.2 AKORN
9.4.3 ALLERGAN INC.
9.4.4 BAYER AG
9.4.5 CIPLA PHARMACEUTICALS
9.4.6 EYEGATE PHARMACEUTICALS
9.4.7 EYEMED
9.4.8 GLAXOSMITHKLINE
9.4.9 JOHNSON AND JOHNSON
9.4.10 LPATH INCORPORATED
9.4.11 MERCK & CO.
9.4.12 BIOTECH VISIONCARE
9.4.13 CARL ZEISS MEDIATEK AG
9.4.14 ELLEX
9.4.15 NIDEK CO. LTD
9.4.16 NOVARTIS AG
9.4.17 PFIZER INC.
9.4.18 REGENERON
9.4.19 ROCHE HOLDING AG
9.4.20 SENJU PHARMACEUTICAL CO., LTD
9.4.21 SUN PHARMACEUTICALS INDUSTRIES, LTD.
9.4.22 SANTEN PHARMACEUTICAL CO.LTD
9.4.23 STAAR SURGICAL COMPANY
9.4.24 TOPCON CORPORATION
9.4.25 VALEANT
9.4.26 VISIONCARE OPHTHALMIC TECHNOLOGIES
9.4.27 ZIEMER OPHTHALMIC SYSTEMS AG
9.4.28 HAAG-STREIT GROUP
9.4.29 IRIDEX CORPORATION
1.1 STUDY GOALS
1.2 SCOPE OF MARKET STUDY
1.3 WHO WILL FIND THIS REPORT USEFUL?
1.4 STUDY AND FORECASTING YEARS
2 RESEARCH METHODOLOGY
2.1 SOURCES OF DATA
2.1.1 SECONDARY DATA
2.1.2 PRIMARY DATA
2.2 TOP DOWN APPROACH
2.3 BOTTOM-UP APPROACH
2.4 DATA TRIANGULATION
3 EXECUTIVE SUMMARY
3.1 KEY FINDINGS
4 MARKET OVERVIEW
4.1 MARKET DEFINITION AND SCOPE
4.2 TOP OPHTHALMIC DRUG BRANDS
5 MARKET DETERMINANTS
5.1 MARKET DRIVERS
5.1.1 INCREASING FDA APPROVALS GIVING A BOOST TO ADOPTION OF DRUGS AND DEVICES
5.1.2 SURGERIES IN OPHTHALMOLOGY MARKET ON RISE DUE TO HIGH PREVALENCE RATE OF REFRACTIVE ERRORS
5.1.3 INCREASING GERIATRIC POPULATION GLOBALLY
5.1.4 RISING PREVALENCE OF EYE DISORDERS
5.1.5 INCREASED HEALTHCARE EXPENDITURE
5.1.6 MINIMALLY INVASIVE SURGERIES ADOPTION ON RISE
5.2 MARKET RESTRAINTS
5.2.1 RENOWNED DRUGS GOING OFF PATENT
5.2.2 MAJOR PLAYERS AFFECTED BY DRYING PIPELINES
5.3 MARKET OPPORTUNITIES
5.3.1 GROWING OPPORTUNITIES IN DEVELOPING ECONOMIES
5.3.2 EMERGING MARKETS PRESENT REMARKABLE GROWTH OPPORTUNITIES
5.4 MARKET CHALLENGES
5.4.1 RISK ASSOCIATED WITH THE OCULAR DISEASES
5.4.2 LACK OF AWARENESS
6 MARKET SEGMENTATION
6.1 BY OPHTHALMIC DEVICES
6.1.1 DIAGNOSTIC & MONITORING EQUIPMENT
6.1.1.1 OPTICAL COHERENCE TOMOGRAPHY SCANNERS
6.1.1.2 OPHTHALMIC ULTRA SOUND IMAGING SYSTEMS
6.1.1.3 FUNDUS CAMERA
6.1.1.4 OPHTHALMOSCOPES
6.1.1.5 RETINOSCOPE
6.1.1.6 PACHYMETER
6.1.1.7 WAVEFRONT ABERROMETERS
6.1.1.8 PERIMETERS/VISUAL FIELD ANALYZER
6.1.1.9 AUTOREFRACTORS/PHOROPTER
6.1.1.10 KERATOMETERS
6.1.1.11 SPECULAR MICROSCOPE
6.1.1.12 CORNEAL TOPOGHAPHERS
6.1.1.13 TONOMETERS
6.1.1.14 SLIT LAMPS
6.1.1.15 BIOMETERS
6.1.1.16 OTHER
6.1.2 SURGERY DEVICE
6.1.2.1 CATARACT SURGERY DEVICE
6.1.2.1.1 INTRAOCULAR LENS
6.1.2.1.2 PHACOEMULSIFICATION DEVICES
6.1.2.1.3 OPHTHALMIC VISCOELASTIC DEVICES
6.1.2.2 GLAUCOMA SURGERY DEVICE
6.1.2.2.1 STENTS AND IMPLANT
6.1.2.2.2 GLAUCOMA DRAINAGE DEVICE
6.1.2.2.3 GLAUCOMA SYSTEM
6.1.2.2.4 GLAUCOMA LASER
6.1.2.3 REFRACTIVE SURGERY DEVICE
6.1.2.3.1 EXCIMER LASER
6.1.2.3.2 EMCROKERATOME
6.1.2.3.3 FEMTOSECOND LASER
6.1.2.3.4 YAG LASER
6.1.2.4 VITREORETINAL SURGERY DEVICE
6.1.2.4.1 PHOTOCOAGULATION LASER
6.1.2.4.2 ILLUMINATION DEVICE
6.1.2.4.3 VITRECTOMY MACHINE
6.2 BY VISION CARE
6.2.1 CONTACT LENS
6.2.2 SPECTACLES
6.2.3 EYE EXAMS
6.3 BY OPHTHALMIC DRUGS
6.3.1 BY PRESCRIPTION TYPE
6.3.1.1 PRESCRIPTION BASED OPHTHALMIC DRUGS
6.3.1.2 OTC (OVER THE COUNTER DRUGS)
6.3.2 BY DRUG DELIVERY TYPES
6.3.2.1 EYE DROPS
6.3.2.2 CAPSULES & TABLET
6.3.2.3 EYE OINTMENT
6.3.2.4 EYE GEL
6.3.2.5 EYE SOLUTION
6.4 BY TYPE OF DISEASE
6.4.1 GLAUCOMA
6.4.1.1 XALATAN (LATANOPROST)/XALACOM (LATANOPROST AND TIMOLOL COMBINATION) (XALABRANDS)
6.4.1.2 LUMIGAN FRANCHISE [LUMIGAN (BIMATOPROST) + GANFORT (BIMATOPROST AND TIMOLOL COMBINATION)]
6.4.1.3 TAPROS/TAFLOTAN (TAFLUPROST)
6.4.1.4 SAFLUTAN/ZIOPTAN (TAFLUPROST)
6.4.1.5 ALPHAGAN (BRIMONIDINE)/COMBIGAN (BRIMONIDINE AND TIMOLOL COMBINATION)
6.4.1.6 COSOPT (DORZOLAMIDE AND TIMOLOL COMBINATION)/ TRUSOPT (DORZOLAMIDE)
6.4.1.7 AZARGA (BRINZOLAMIDE AND TIMOLOL COMBINATION)
6.4.1.8 AZOPT (BRINZOLAMIDE)
6.4.2 RETINAL DISORDER
6.4.2.1 LUCENTIS (RANIBIZUMAB)
6.4.2.2 VISUDYNE (VERTEPORFIN)
6.4.2.3 AVASTIN (BEVACIZUMAB)
6.4.2.4 EYLEA (AFLIBERCEPT)
6.4.3 DRY EYE DRUG
6.4.3.1 RESTASIS (CYCLOSPORINE)
6.4.3.2 HYALEIN (SODIUM HYALURONATE)
6.4.3.3 DIQUAS (DIQUAFOSOL SODIUM)
6.4.4 ALLERGIC CONJUNCTIVITIS, INFLAMMATION AND CONJUNCTIVITIS DRUGS
6.4.4.1 PATANOL/PATADAY/OPATANOL (OLOPATADINE)
6.4.4.2 BEPREVE (BEPOTASTINE BESILATE)
6.4.4.3 TOBRADEX (TOBRAMYCIN & DEXAMETHASONE COMBINATION)
6.4.4.4 XIBROM/BROMDAY (BROMFENAC)
6.4.4.5 VIGAMOX
6.4.4.6 AZASITE (AZITHROMYCIN)
6.5 BY THERAPEUTICS
6.5.1 DIABETIC MACULAR EDEMA
6.5.2 EYE CANCER
6.5.3 DIABETIC RETINOPATHY
6.5.4 RETINAL VEIN OCCLUSION
6.5.5 AGE-RELATED MACULAR DEGENERATION
6.5.6 CONJUNCTIVITIS
6.5.7 DRY EYE
6.5.8 GLAUCOMA
6.5.9 KERATITIS
6.5.10 GEOGRAPHIC ATROPHY
6.6 BY END USER
6.6.1 HOSPITALS
6.6.2 EYE CLINICS
6.6.3 DIAGNOSTIC CENTERS
6.6.4 PATIENTS
7 KEY ANALYTICS
7.1 PORTER’S FIVE FORCE ANALYSIS
7.1.1 BARGAINING POWER BUYERS
7.1.2 BARGAINING POWER OF SUPPLIER
7.1.3 THREATS OF NEW ENTARANTS
7.1.4 THREATS OF SUBSTITUTES
7.1.5 COMPETITIVE RIVALRY
7.2 VALUE CHAIN ANALYSIS
7.2.1 SUPPLIERS
7.2.2 MANUFACTURERS
7.2.3 DISTRIBUTORS AND RETAILERS
7.2.4 END USERS
7.3 KEY BUYING CRITERIA
7.4 KEY MARKET INSIGHTS
7.4.1 TOP 3 EMERGING COUNTRIES
7.4.2 TOP REVENUE GENERATING SEGMENTS
7.4.3 TOP GROWING MARKETS AND EMERGING TRENDS
7.4.4 R&D SCENARIO IN OPHTHALMOLOGY MARKET
7.4.4.1 PLASMA TECHNOLOGY IN OPHTHALMOLOGY
7.4.4.2 CORNIAL TOPOGRAPHY & CORNIAL ANALYSIS
7.4.4.3 SCOPE OF VIRTUAL REALITY TECHNOLOGY IN EYE CARE
7.5 SECTOR ANALYSIS
7.5.1 PARENT MARKET
7.5.2 SUB-SEGMENT MARKET
7.5.3 ALTERNATIVE MARKET
7.6 STRATEGIC RECOMMENDATION
7.7 STRATEGIC CONCLUSIONS
8 GEOGRAPHIC ANALYSIS
8.1 NORTH AMERICA
8.1.1 UNITED STATES (U.S.)
8.1.2 CANADA
8.2 EUROPE
8.2.1 UNITED KINGDOM (UK)
8.2.2 FRANCE
8.2.3 GERMANY
8.2.4 SPAIN
8.2.5 ITALY
8.2.6 REST OF EUROPE (ROE)
8.3 ASIA PACIFIC
8.3.1 INDIA
8.3.2 CHINA
8.3.3 JAPAN
8.3.4 SOUTH KOREA
8.3.5 AUSTRALIA
8.3.6 ROAPAC
8.4 REST OF THE WORLD
8.4.1 LATIN AMERICA
8.4.2 MIDDLE EAST & AFRICA
9 COMPETITIVE LANDSCAPE
9.1 MARKET SHARE ANALYSIS
9.2 TOP WINNING STRATEGIES
9.3 CASE STUDIES: TOP COMPETITIVE MOVES
9.4 COMPANY PROFILES
9.4.1 ABBOTT LABORATORIES
9.4.2 AKORN
9.4.3 ALLERGAN INC.
9.4.4 BAYER AG
9.4.5 CIPLA PHARMACEUTICALS
9.4.6 EYEGATE PHARMACEUTICALS
9.4.7 EYEMED
9.4.8 GLAXOSMITHKLINE
9.4.9 JOHNSON AND JOHNSON
9.4.10 LPATH INCORPORATED
9.4.11 MERCK & CO.
9.4.12 BIOTECH VISIONCARE
9.4.13 CARL ZEISS MEDIATEK AG
9.4.14 ELLEX
9.4.15 NIDEK CO. LTD
9.4.16 NOVARTIS AG
9.4.17 PFIZER INC.
9.4.18 REGENERON
9.4.19 ROCHE HOLDING AG
9.4.20 SENJU PHARMACEUTICAL CO., LTD
9.4.21 SUN PHARMACEUTICALS INDUSTRIES, LTD.
9.4.22 SANTEN PHARMACEUTICAL CO.LTD
9.4.23 STAAR SURGICAL COMPANY
9.4.24 TOPCON CORPORATION
9.4.25 VALEANT
9.4.26 VISIONCARE OPHTHALMIC TECHNOLOGIES
9.4.27 ZIEMER OPHTHALMIC SYSTEMS AG
9.4.28 HAAG-STREIT GROUP
9.4.29 IRIDEX CORPORATION
LIST OF TABLES
TABLE 1 GLOBAL OPHTHALMIC DRUGS AND DEVICE MARKET BY PRODUCT 2017-2025 ($ MILLION)
TABLE 2 TOP OPHTHALMIC DRUGS BRANDS
TABLE 3 DRUGS AND DEVICES APPROVED BY FDA
TABLE 4 SYMPTOMS OF SOME COMMON CAUSES OF LOSS OF VISION IN ELDERLY PATIENTS
TABLE 5 EYE DRUGS GONE PATENT OFF
TABLE 6 FACTS ABOUT CATARACT SURGERIES FROM DEVELOPING ECONOMIES
TABLE 7 GLOBAL OPHTHALMIC DEVICE MARKET BY GEOGRAPHY 2017-2025($MILLION)
TABLE 8 GLOBAL OPHTHALMIC DEVICE MARKET 2017-2025 ($ MILLION)
TABLE 9 GLOBAL OPHTHALMIC DIAGNOSTIC & MONITORING EQUIPMENT MARKET 2017-2025 ($ MILLION)
TABLE 10 SCANS PERFORMED BY DOMAINS
TABLE 11 GLOBAL OPTICAL COHERENCE TOMOGRAPHY SCANNERS MARKET BY GEOGRAPHY 2017-2025 ($ MILLION)
TABLE 12 DIFFERENCE BETWEEN A-SCAN AND B-SCAN SOUND WAVES GENERATION
TABLE 13 GLOBAL OPHTHALMIC ULTRASOUND IMAGING SYSTEMS MARKET BY GEOGRAPHY 2017-2025 ($ MILLION)
TABLE 14 GLOBAL FUNDUS CAMERA MARKET BY GEOGRAPHY 2017-2025 ($ MILLION)
TABLE 15 COMPARISON BETWEEN DIRECT AND INDIRECT OPHTHALMOSCOPY
TABLE 16 GLOBAL OPHTHALMOSCOPES MARKET BY GEOGRAPHY 2017-2025 ($ MILLION)
TABLE 17 GLOBAL RETINOSCOPE MARKET BY GEOGRAPHY 2017-2025 ($ MILLION)
TABLE 18 GLOBAL PACHYMETER MARKET BY GEOGRAPHY 2017-2025 ($ MILLION)
TABLE 19 GLOBAL WAVEFRONT ABERROMETERS MARKET BY GEOGRAPHY 2017-2025 ($ MILLION)
TABLE 20 GLOBAL PERIMETERS/VISUAL FIELD ANALYZER MARKET BY GEOGRAPHY 2017-2025 ($ MILLION)
TABLE 21 GLOBAL AUTOREFRACTORS/PHOROPTER MARKET BY GEOGRAPHY 2017-2025 ($ MILLION)
TABLE 22 GLOBAL KERATOMETERS MARKET BY GEOGRAPHY 2017-2025 ($ MILLION)
TABLE 23 GLOBAL SPECULAR MICROSCOPE MARKET BY GEOGRAPHY 2017-2025 ($ MILLION)
TABLE 24 GLOBAL CORNEAL TOPOGRAPHERS MARKET BY GEOGRAPHY 2017-2025 ($ MILLION)
TABLE 25 GLOBAL TONOMETERS MARKET BY GEOGRAPHY 2017-2025 ($ MILLION)
TABLE 26 GLOBAL SLIT LAMPS MARKET BY GEOGRAPHY 2017-2025 ($ MILLION)
TABLE 27 GLOBAL BIOMETERS MARKET BY GEOGRAPHY 2017-2025 ($ MILLION)
TABLE 28 GLOBAL OTHER MARKET BY GEOGRAPHY 2017-2025 ($ MILLION)
TABLE 29 GLOBAL OPHTHALMIC SURGERY DEVICE MARKET 2017-2025 ($ MILLION)
TABLE 30 GLOBAL CATARACT SURGERY DEVICE MARKET BY GEOGRAPHY 2017-2025 ($ MILLION)
TABLE 31 GLOBAL GLAUCOMA SURGERY DEVICE MARKET BY GEOGRAPHY 2017-2025 ($ MILLION)
TABLE 32 GLOBAL REFRACTIVE SURGERY DEVICE MARKET BY GEOGRAPHY 2017-2025 ($ MILLION)
TABLE 33 GLOBAL VITREORETINAL SURGERY DEVICE MARKET BY GEOGRAPHY 2017-2025 ($ MILLION)
TABLE 34 PATENT FOR ILLUMINATION SYSTEM IN OPHTHALMIC SURGERY 2015
TABLE 35 GLOBAL VISION CARE MARKET BY DEVICE 2017-2025 ($ MILLION)
TABLE 36 GLOBAL VISION CARE DEVICE MARKET BY GEOGRAPHY 2017-2025 ($ MILLION)
TABLE 37 GLOBAL CONTACT LENS MARKET BY GEOGRAPHY 2017-2025 ($ MILLION)
TABLE 38 GLOBAL SPECTACLES MARKET BY GEOGRAPHY 2017-2025 ($ MILLION)
TABLE 39 EYE EXAMS AMONG VARIOUS AGE INDIVIDUALS
TABLE 40 GLOBAL EYE EXAMS MARKET BY GEOGRAPHY 2017-2025 ($ MILLION)
TABLE 41 GLOBAL OPHTHALMIC DRUG MARKET BY GEOGRAPHY 2017-2025 ($ MILLION)
TABLE 42 GLOBAL OPHTHALMIC DRUGS MARKET BY PRESCRIPTION TYPE 2017-2025 ($ MILLION)
TABLE 43 VARIOUS FDA- APPROVED DRUGS FOR OPHTHALMOLOGY
TABLE 44 FDA-APPROVED PRESCRIPTION DRUG INFORMATION
TABLE 45 OPHTHALMIC DRUG PRODUCTS FOR OVER-THE-COUNTER HUMAN USE
TABLE 46 GLOBAL OPHTHALMOLOGY DRUG MARKET BY DELIVERY TYPES 2017-2025 ($ MILLION)
TABLE 47 TOP SELLING EYE DROPS 2016
TABLE 48 GLOBAL EYE DROPS MARKET BY GEOGRAPHY 2017-2025 ($ MILLION)
TABLE 49 TOP SELLING EYE SUPPLEMENTS BRANDS IN US IN 2014
TABLE 50 GLOBAL OPHTHALMOLOGY CAPSULES & TABLET MARKET BY GEOGRAPHY 2017-2025 ($ MILLION)
TABLE 51 TOP SELLING EYE OINTMENT IN US 2015
TABLE 52 GLOBAL EYE OINTMENT MARKET BY GEOGRAPHY 2017-2025 ($ MILLION)
TABLE 53 GLOBAL EYE GEL MARKET BY GEOGRAPHY 2017-2025 ($ MILLION)
TABLE 54 TOP SELLING EYE SOLUTION IN US 2015
TABLE 55 GLOBAL EYE SOLUTION MARKET BY GEOGRAPHY 2017-2025 ($ MILLION)
TABLE 56 GLOBAL GLAUCOMA DRUG MARKET BY GEOGRAPHY 2017-2025 ($ MILLION)
TABLE 57 GLOBAL RETINAL DISORDER MARKET BY GEOGRAPHY 2017-2025 ($ MILLION)
TABLE 58 GLOBAL DRY EYE DRUG MARKET BY GEOGRAPHY 2017-2025 ($ MILLION)
TABLE 59 GLOBAL ALLERGIC CONJUNCTIVITIS, INFLAMMATION AND CONJUNCTIVITIS DRUGS MARKET BY GEOGRAPHY 2017-2025($ MILLION)
TABLE 60 GLOBAL OPHTHALMIC DRUG AND DEVICE MARKET BY THERAPEUTICS 2017-2025 ($ MILLION)
TABLE 61 SYMPTOMS, TREATMENT, AND RECOVERY TIME FOR DIABETIC MACULAR EDEMA
TABLE 62 GLOBAL DIABETIC MACULAR EDEMA MARKET BY GEOGRAPHY 2017-2025 ($ MILLION)
TABLE 63 SYMPTOMS AND TREATMENT FOR EYE CANCER
TABLE 64 GLOBAL EYE CANCER MARKET BY GEOGRAPHY 2017-2025 ($ MILLION)
TABLE 65 GLOBAL DIABETIC RETINOPATHY MARKET BY GEOGRAPHY 2017-2025 ($ MILLION)
TABLE 66 GLOBAL RETINAL VEIN OCCLUSION MARKET BY GEOGRAPHY 2017-2025 ($ MILLION)
TABLE 67 GLOBAL AGE-RELATED MACULAR DEGENERATION MARKET BY GEOGRAPHY 2017-2025 ($ MILLION)
TABLE 68 GLOBAL CONJUNCTIVITIS MARKET BY GEOGRAPHY 2017-2025 ($ MILLION)
TABLE 69 GLOBAL DRY EYE MARKET BY GEOGRAPHY 2017-2025 ($ MILLION)
TABLE 70 GLOBAL GLAUCOMA THERAPEUTICS MARKET BY GEOGRAPHY 2017-2025 ($ MILLION)
TABLE 71 GLOBAL KERATITIS MARKET BY GEOGRAPHY 2017-2025 ($ MILLION)
TABLE 72 GLOBAL GEOGRAPHIC ATROPHY MARKET BY GEOGRAPHY 2017-2025 ($ MILLION)
TABLE 73 GLOBAL OPHTHALMIC DRUGS & DEVICES MARKET BY END USER 2017-2025 ($ MILLION)
TABLE 74 GLOBAL HOSPITALS MARKET BY GEOGRAPHY 2017-2025 ($ MILLION)
TABLE 75 GLOBAL EYE CLINICS MARKET BY GEOGRAPHY 2017-2025 ($ MILLION)
TABLE 76 GLOBAL DIAGNOSTIC CENTERS MARKET BY GEOGRAPHY 2017-2025 ($ MILLION)
TABLE 77 GLOBAL PATIENTS OPHTHALMIC DRUGS MARKET BY GEOGRAPHY 2017-2025 ($ MILLION)
TABLE 78 APPLICATION OF VIRTUAL REALITY IN EYE CARE
TABLE 79 CASE STUDY OF VIRTUAL REALITY IN GLAUCOMA RESEARCH
TABLE 80 GLOBAL OPHTHALMIC DRUGS & DEVICES MARKET BY GEOGRAPHY 2017-2025 ($ MILLION)
TABLE 81 INITIATIVES FOR EYE CARE IN NORTH AMERICA
TABLE 82 NORTH AMERICA OPHTHALMIC DRUGS & DEVICES MARKET BY COUNTRIES 2017-2025 ($ MILLION)
TABLE 83 US OPHTHALMIC DRUGS & DEVICE MARKET BY PRODUCT 2017-2025 ($ MILLION)
TABLE 84 US OPHTHALMIC DRUGS & DEVICES MARKET BY THERAPEUTICS 2017-2025 ($ MILLION)
TABLE 85 U.S. HOSPITAL FACT SHEET, 2016
TABLE 86 US OPHTHALMIC DEVICE MARKET BY TYPE 2017-2025($ MILLION)
TABLE 87 US VISION CARE DEVICES MARKET BY VISION CARE 2017-2025 ($ MILLION)
TABLE 88 US OPHTHALMIC DRUGS MARKET BY TYPE OF DISEASE 2017-2025 ($ MILLION)
TABLE 89 US OPHTHALMIC DRUGS MARKET BY DELIVERY TYPE 2017-2025($ MILLION)
TABLE 90 INITIATIVES FOR EYE CARE IN EUROPE
TABLE 91 EUROPE OPHTHALMIC DRUGS & DEVICES MARKET BY COUNTRIES 2017-2025 ($ MILLION)
TABLE 92 SCENARIO OF HOSPITALS IN RUSSIA 2016
TABLE 93 ASIA-PACIFIC OPHTHALMIC DRUGS & DEVICES MARKET BY COUNTRIES 2017-2025 ($ MILLION)
TABLE 94 INITIATIVES FOR EYE CARE IN ASIA PACIFIC REGION
TABLE 95 PERSONNEL NEEDED FOR EYECARE IN INDIA
TABLE 96 PREVALENCE RATE OF EYE RELATED DISEASES IN CHINA 2014
TABLE 97 EYE HEALTH STATISTICS IN AUSTRALIA
TABLE 98 KEY CAUSES OF BLINDNESS IN INDONESIA
TABLE 99 REST OF ASIA-PACIFIC OPHTHALMIC DRUGS & DEVICES MARKET 2017-2025 ($ MILLION)
TABLE 100 REST OF THE WORLD OPHTHALMIC DRUGS & DEVICES MARKET BY REGION 2017-2025 ($ MILLION)
TABLE 101 TOP WINNING STRATEGIES
TABLE 1 GLOBAL OPHTHALMIC DRUGS AND DEVICE MARKET BY PRODUCT 2017-2025 ($ MILLION)
TABLE 2 TOP OPHTHALMIC DRUGS BRANDS
TABLE 3 DRUGS AND DEVICES APPROVED BY FDA
TABLE 4 SYMPTOMS OF SOME COMMON CAUSES OF LOSS OF VISION IN ELDERLY PATIENTS
TABLE 5 EYE DRUGS GONE PATENT OFF
TABLE 6 FACTS ABOUT CATARACT SURGERIES FROM DEVELOPING ECONOMIES
TABLE 7 GLOBAL OPHTHALMIC DEVICE MARKET BY GEOGRAPHY 2017-2025($MILLION)
TABLE 8 GLOBAL OPHTHALMIC DEVICE MARKET 2017-2025 ($ MILLION)
TABLE 9 GLOBAL OPHTHALMIC DIAGNOSTIC & MONITORING EQUIPMENT MARKET 2017-2025 ($ MILLION)
TABLE 10 SCANS PERFORMED BY DOMAINS
TABLE 11 GLOBAL OPTICAL COHERENCE TOMOGRAPHY SCANNERS MARKET BY GEOGRAPHY 2017-2025 ($ MILLION)
TABLE 12 DIFFERENCE BETWEEN A-SCAN AND B-SCAN SOUND WAVES GENERATION
TABLE 13 GLOBAL OPHTHALMIC ULTRASOUND IMAGING SYSTEMS MARKET BY GEOGRAPHY 2017-2025 ($ MILLION)
TABLE 14 GLOBAL FUNDUS CAMERA MARKET BY GEOGRAPHY 2017-2025 ($ MILLION)
TABLE 15 COMPARISON BETWEEN DIRECT AND INDIRECT OPHTHALMOSCOPY
TABLE 16 GLOBAL OPHTHALMOSCOPES MARKET BY GEOGRAPHY 2017-2025 ($ MILLION)
TABLE 17 GLOBAL RETINOSCOPE MARKET BY GEOGRAPHY 2017-2025 ($ MILLION)
TABLE 18 GLOBAL PACHYMETER MARKET BY GEOGRAPHY 2017-2025 ($ MILLION)
TABLE 19 GLOBAL WAVEFRONT ABERROMETERS MARKET BY GEOGRAPHY 2017-2025 ($ MILLION)
TABLE 20 GLOBAL PERIMETERS/VISUAL FIELD ANALYZER MARKET BY GEOGRAPHY 2017-2025 ($ MILLION)
TABLE 21 GLOBAL AUTOREFRACTORS/PHOROPTER MARKET BY GEOGRAPHY 2017-2025 ($ MILLION)
TABLE 22 GLOBAL KERATOMETERS MARKET BY GEOGRAPHY 2017-2025 ($ MILLION)
TABLE 23 GLOBAL SPECULAR MICROSCOPE MARKET BY GEOGRAPHY 2017-2025 ($ MILLION)
TABLE 24 GLOBAL CORNEAL TOPOGRAPHERS MARKET BY GEOGRAPHY 2017-2025 ($ MILLION)
TABLE 25 GLOBAL TONOMETERS MARKET BY GEOGRAPHY 2017-2025 ($ MILLION)
TABLE 26 GLOBAL SLIT LAMPS MARKET BY GEOGRAPHY 2017-2025 ($ MILLION)
TABLE 27 GLOBAL BIOMETERS MARKET BY GEOGRAPHY 2017-2025 ($ MILLION)
TABLE 28 GLOBAL OTHER MARKET BY GEOGRAPHY 2017-2025 ($ MILLION)
TABLE 29 GLOBAL OPHTHALMIC SURGERY DEVICE MARKET 2017-2025 ($ MILLION)
TABLE 30 GLOBAL CATARACT SURGERY DEVICE MARKET BY GEOGRAPHY 2017-2025 ($ MILLION)
TABLE 31 GLOBAL GLAUCOMA SURGERY DEVICE MARKET BY GEOGRAPHY 2017-2025 ($ MILLION)
TABLE 32 GLOBAL REFRACTIVE SURGERY DEVICE MARKET BY GEOGRAPHY 2017-2025 ($ MILLION)
TABLE 33 GLOBAL VITREORETINAL SURGERY DEVICE MARKET BY GEOGRAPHY 2017-2025 ($ MILLION)
TABLE 34 PATENT FOR ILLUMINATION SYSTEM IN OPHTHALMIC SURGERY 2015
TABLE 35 GLOBAL VISION CARE MARKET BY DEVICE 2017-2025 ($ MILLION)
TABLE 36 GLOBAL VISION CARE DEVICE MARKET BY GEOGRAPHY 2017-2025 ($ MILLION)
TABLE 37 GLOBAL CONTACT LENS MARKET BY GEOGRAPHY 2017-2025 ($ MILLION)
TABLE 38 GLOBAL SPECTACLES MARKET BY GEOGRAPHY 2017-2025 ($ MILLION)
TABLE 39 EYE EXAMS AMONG VARIOUS AGE INDIVIDUALS
TABLE 40 GLOBAL EYE EXAMS MARKET BY GEOGRAPHY 2017-2025 ($ MILLION)
TABLE 41 GLOBAL OPHTHALMIC DRUG MARKET BY GEOGRAPHY 2017-2025 ($ MILLION)
TABLE 42 GLOBAL OPHTHALMIC DRUGS MARKET BY PRESCRIPTION TYPE 2017-2025 ($ MILLION)
TABLE 43 VARIOUS FDA- APPROVED DRUGS FOR OPHTHALMOLOGY
TABLE 44 FDA-APPROVED PRESCRIPTION DRUG INFORMATION
TABLE 45 OPHTHALMIC DRUG PRODUCTS FOR OVER-THE-COUNTER HUMAN USE
TABLE 46 GLOBAL OPHTHALMOLOGY DRUG MARKET BY DELIVERY TYPES 2017-2025 ($ MILLION)
TABLE 47 TOP SELLING EYE DROPS 2016
TABLE 48 GLOBAL EYE DROPS MARKET BY GEOGRAPHY 2017-2025 ($ MILLION)
TABLE 49 TOP SELLING EYE SUPPLEMENTS BRANDS IN US IN 2014
TABLE 50 GLOBAL OPHTHALMOLOGY CAPSULES & TABLET MARKET BY GEOGRAPHY 2017-2025 ($ MILLION)
TABLE 51 TOP SELLING EYE OINTMENT IN US 2015
TABLE 52 GLOBAL EYE OINTMENT MARKET BY GEOGRAPHY 2017-2025 ($ MILLION)
TABLE 53 GLOBAL EYE GEL MARKET BY GEOGRAPHY 2017-2025 ($ MILLION)
TABLE 54 TOP SELLING EYE SOLUTION IN US 2015
TABLE 55 GLOBAL EYE SOLUTION MARKET BY GEOGRAPHY 2017-2025 ($ MILLION)
TABLE 56 GLOBAL GLAUCOMA DRUG MARKET BY GEOGRAPHY 2017-2025 ($ MILLION)
TABLE 57 GLOBAL RETINAL DISORDER MARKET BY GEOGRAPHY 2017-2025 ($ MILLION)
TABLE 58 GLOBAL DRY EYE DRUG MARKET BY GEOGRAPHY 2017-2025 ($ MILLION)
TABLE 59 GLOBAL ALLERGIC CONJUNCTIVITIS, INFLAMMATION AND CONJUNCTIVITIS DRUGS MARKET BY GEOGRAPHY 2017-2025($ MILLION)
TABLE 60 GLOBAL OPHTHALMIC DRUG AND DEVICE MARKET BY THERAPEUTICS 2017-2025 ($ MILLION)
TABLE 61 SYMPTOMS, TREATMENT, AND RECOVERY TIME FOR DIABETIC MACULAR EDEMA
TABLE 62 GLOBAL DIABETIC MACULAR EDEMA MARKET BY GEOGRAPHY 2017-2025 ($ MILLION)
TABLE 63 SYMPTOMS AND TREATMENT FOR EYE CANCER
TABLE 64 GLOBAL EYE CANCER MARKET BY GEOGRAPHY 2017-2025 ($ MILLION)
TABLE 65 GLOBAL DIABETIC RETINOPATHY MARKET BY GEOGRAPHY 2017-2025 ($ MILLION)
TABLE 66 GLOBAL RETINAL VEIN OCCLUSION MARKET BY GEOGRAPHY 2017-2025 ($ MILLION)
TABLE 67 GLOBAL AGE-RELATED MACULAR DEGENERATION MARKET BY GEOGRAPHY 2017-2025 ($ MILLION)
TABLE 68 GLOBAL CONJUNCTIVITIS MARKET BY GEOGRAPHY 2017-2025 ($ MILLION)
TABLE 69 GLOBAL DRY EYE MARKET BY GEOGRAPHY 2017-2025 ($ MILLION)
TABLE 70 GLOBAL GLAUCOMA THERAPEUTICS MARKET BY GEOGRAPHY 2017-2025 ($ MILLION)
TABLE 71 GLOBAL KERATITIS MARKET BY GEOGRAPHY 2017-2025 ($ MILLION)
TABLE 72 GLOBAL GEOGRAPHIC ATROPHY MARKET BY GEOGRAPHY 2017-2025 ($ MILLION)
TABLE 73 GLOBAL OPHTHALMIC DRUGS & DEVICES MARKET BY END USER 2017-2025 ($ MILLION)
TABLE 74 GLOBAL HOSPITALS MARKET BY GEOGRAPHY 2017-2025 ($ MILLION)
TABLE 75 GLOBAL EYE CLINICS MARKET BY GEOGRAPHY 2017-2025 ($ MILLION)
TABLE 76 GLOBAL DIAGNOSTIC CENTERS MARKET BY GEOGRAPHY 2017-2025 ($ MILLION)
TABLE 77 GLOBAL PATIENTS OPHTHALMIC DRUGS MARKET BY GEOGRAPHY 2017-2025 ($ MILLION)
TABLE 78 APPLICATION OF VIRTUAL REALITY IN EYE CARE
TABLE 79 CASE STUDY OF VIRTUAL REALITY IN GLAUCOMA RESEARCH
TABLE 80 GLOBAL OPHTHALMIC DRUGS & DEVICES MARKET BY GEOGRAPHY 2017-2025 ($ MILLION)
TABLE 81 INITIATIVES FOR EYE CARE IN NORTH AMERICA
TABLE 82 NORTH AMERICA OPHTHALMIC DRUGS & DEVICES MARKET BY COUNTRIES 2017-2025 ($ MILLION)
TABLE 83 US OPHTHALMIC DRUGS & DEVICE MARKET BY PRODUCT 2017-2025 ($ MILLION)
TABLE 84 US OPHTHALMIC DRUGS & DEVICES MARKET BY THERAPEUTICS 2017-2025 ($ MILLION)
TABLE 85 U.S. HOSPITAL FACT SHEET, 2016
TABLE 86 US OPHTHALMIC DEVICE MARKET BY TYPE 2017-2025($ MILLION)
TABLE 87 US VISION CARE DEVICES MARKET BY VISION CARE 2017-2025 ($ MILLION)
TABLE 88 US OPHTHALMIC DRUGS MARKET BY TYPE OF DISEASE 2017-2025 ($ MILLION)
TABLE 89 US OPHTHALMIC DRUGS MARKET BY DELIVERY TYPE 2017-2025($ MILLION)
TABLE 90 INITIATIVES FOR EYE CARE IN EUROPE
TABLE 91 EUROPE OPHTHALMIC DRUGS & DEVICES MARKET BY COUNTRIES 2017-2025 ($ MILLION)
TABLE 92 SCENARIO OF HOSPITALS IN RUSSIA 2016
TABLE 93 ASIA-PACIFIC OPHTHALMIC DRUGS & DEVICES MARKET BY COUNTRIES 2017-2025 ($ MILLION)
TABLE 94 INITIATIVES FOR EYE CARE IN ASIA PACIFIC REGION
TABLE 95 PERSONNEL NEEDED FOR EYECARE IN INDIA
TABLE 96 PREVALENCE RATE OF EYE RELATED DISEASES IN CHINA 2014
TABLE 97 EYE HEALTH STATISTICS IN AUSTRALIA
TABLE 98 KEY CAUSES OF BLINDNESS IN INDONESIA
TABLE 99 REST OF ASIA-PACIFIC OPHTHALMIC DRUGS & DEVICES MARKET 2017-2025 ($ MILLION)
TABLE 100 REST OF THE WORLD OPHTHALMIC DRUGS & DEVICES MARKET BY REGION 2017-2025 ($ MILLION)
TABLE 101 TOP WINNING STRATEGIES
LIST OF FIGURES
FIGURE 1 KEY FINDINGS OF THE REPORT
FIGURE 2 GLOBAL GERIATRIC POPULATION (65+) 2015 & 2020 (MILLION)
FIGURE 3 PROJECTIONS FOR THE PROPORTION OF GLOBAL GERIATRIC (60+) POPULATION
FIGURE 4 WORLDWIDE PREVALENCE OF PRESBYOPIA (BILLION)
FIGURE 5 PREVALENCE OF GLAUCOMA AT GLOBAL LEVEL (MILLION)
FIGURE 6 GLOBAL HEALTHCARE EXPENDITURE (% OF GDP) 2012-2014
FIGURE 7 HEALTHCARE EXPENDITURE OF DEVELOPED ECONOMIES AS % OF THEIR GDP IN 2014
FIGURE 8 HEALTHCARE EXPENDITURE OF DEVELOPING ECONOMIES AS % OF THEIR GDP IN 2014
FIGURE 9 HEALTHCARE EXPENDITURE (AS % OF GDP) OF MAJOR APAC COUNTRIES IN 2014
FIGURE 10 GROWTH IN GERIATRIC POPULATION FROM 2010 TO 2015(%)
FIGURE 11 RISK ASSOCIATED WITH THE OCULAR DISEASES
FIGURE 12 CAUSES OF BLINDNESS WORLDWIDE
FIGURE 13 GLOBAL CATARACT SURGERY DEVICE MARKET 2017-2025 ($ MILLION)
FIGURE 14 GLOBAL GLAUCOMA SURGERY DEVICE MARKET 2017-2025 ($ MILLION)
FIGURE 15 GLOBAL REFRACTIVE SURGERY DEVICE MARKET 2017-2025 ($ MILLION)
FIGURE 16 GLOBAL VITREORETINAL SURGERY DEVICE MARKET 2017-2025 ($ MILLION)
FIGURE 17 GLOBAL CONTACT LENS MARKET 2017-2025 ($ MILLION)
FIGURE 18 CONTACT LENS USAGE AMONG VARIOUS AGE GROUPS IN THE U.S. 2015
FIGURE 19 GLOBAL SPECTACLES MARKET 2017-2025 ($ MILLION)
FIGURE 20 EYE EXAMS IN THE U.S. ADULTS 2012-2014 (MILLION)
FIGURE 21 CONSUMPTION OF DRUGS BY TYPES IN 2016
FIGURE 22 GLOBAL EYE DROPS MARKET 2017-2025 ($ MILLION)
FIGURE 23 USAGE OF EYE DROPS AND EYE WASH IN U.S. HOUSEHOLDS 2012-2015 (%)
FIGURE 24 GLOBAL CAPSULES & TABLET MARKET 2017-2025 ($ MILLION)
FIGURE 25 GLOBAL EYE OINTMENT MARKET 2017-2025 ($ MILLION)
FIGURE 26 GLOBAL EYE GEL MARKET 2017-2025 ($ MILLION)
FIGURE 27 GLOBAL EYE SOLUTION MARKET 2017-2025 ($ MILLION)
FIGURE 28 GLOBAL GLAUCOMA DRUG MARKET 2017-2025 ($ MILLION)
FIGURE 29 DIFFERENT AGE GROUP WITH PROBABILITY OF BEING AFFECTED 2016
FIGURE 30 GLOBAL RETINAL DISORDER DRUGS MARKET 2017-2025 ($ MILLION)
FIGURE 31 GLOBAL DRY EYE DRUG MARKET 2017-2025($ MILLION)
FIGURE 32 GLOBAL ALLERGIC CONJUNCTIVITIS, INFLAMMATION AND CONJUNCTIVITIS DRUGS MARKET 2017-2025 ($ MILLION)
FIGURE 33 DIABETIC RETINOPATHY PREVALENCE IN THE U.S. 2011 & 2030 (MILLION)
FIGURE 34 TOTAL OPHTHALMIC CARE HOSPITAL IN US 2014
FIGURE 35 EYE DISEASES CASES ABOVE AGE OF 40 IN AMERICA 2014 (MILLION)
FIGURE 36 TOTAL VISUAL IMPAIRMENT AND BLINDNESS CASES ABOVE AGE 40 IN US IN 2014 (MILLION)
FIGURE 37 CASES ABOVE 40 AGE IN AMERICA 2014 (MILLION)
FIGURE 38 VALUE CHAIN ANALYSIS: OPHTHALMIC DRUGS MARKET
FIGURE 39 VALUE CHAIN ANALYSIS OF OPHTHALMIC DEVICES MARKET
FIGURE 40 KEY BUYING CRITERIA
FIGURE 41 KEY BUYING CRITERIA IMPACT
FIGURE 42 TOP REVENUE GENERATING SEGMENTS 2017-2025 ($ MILLION)
FIGURE 43 BENEFITS SUPPORTING HIGHER CATARACT SURGERIES
FIGURE 44 MAJOR RESEARCH AND DEVELOPMENT AREAS IN PLASMA TECHNOLOGY IN OPHTHALMOLOGY
FIGURE 45 NUMBER OF CLINICS USING VR SYSTEMS IN VARIOUS GEOGRAPHIES
FIGURE 46 KEY MARKET FACTS
FIGURE 47 VISION SCREENING PERFORMED BY EACH GROUP OF PROVIDERS (IN %)
FIGURE 48 ATTRACTIVE INVESTMENT PROPOSITION BY SEGMENT 2016 ($ MILLION)
FIGURE 49 ATTRACTIVE INVESTMENT PROPOSITION BY GEOGRAPHY 2016 ($ MILLION)
FIGURE 50 UNITED STATES (U.S.) MARKET 2017-2025 ($ MILLION)
FIGURE 51 CAUSES OF VISUAL IMPAIRMENT IN THE U.S. 2016
FIGURE 52 PREVALENCE RATE OF RETINAL DISORDERS IN CANADA, 2016
FIGURE 53 FINANCIAL COST SHARE OF RETINA DISORDER TREATMENT IN CANADA
FIGURE 54 GERIATRIC POPULATION IN EUROPE (65 YEARS AND ABOVE)
FIGURE 55 OPTOMETRISTS AND OPTICIANS PERCENTAGE IN EUROPEAN COUNTRIES 2016
FIGURE 56 ESTIMATED NUMBER OF PEOPLE HAVING SIGHT LOSS IN UK (MILLION)
FIGURE 57 UK OPHTHALMIC DRUGS & DEVICES MARKET 2017-2025 ($ MILLION)
FIGURE 58 FRANCE OPHTHALMIC DRUGS & DEVICES MARKET 2017-2025 ($ MILLION)
FIGURE 59 NUMBER OF LASIK SURGERIES IN GERMANY 2012-2020 (1000’S)
FIGURE 60 GERMANY OPHTHALMIC DRUGS & DEVICES MARKET 2017-2025 ($ MILLION)
FIGURE 61 GERIATRIC POPULATION IN SPAIN 65 YEARS AND ABOVE (% OF POPULATION)
FIGURE 62 SPAIN OPHTHALMIC DRUGS & DEVICES MARKET 2017-2025 ($ MILLION)
FIGURE 63 ITALY OPHTHALMIC DRUGS & DEVICES MARKET 2017-2025 ($ MILLION)
FIGURE 64 REST OF EUROPE OPHTHALMIC DRUGS & DEVICES MARKET 2017-2025 ($ MILLION)
FIGURE 65 HEALTHCARE EXPENDITURE IN ASIA-PACIFIC COUNTRIES
FIGURE 66 INDIA OPHTHALMIC DRUGS & DEVICES MARKET 2017-2025 ($ MILLION)
FIGURE 67 CHINA OPHTHALMIC DRUGS & DEVICES MARKET 2017-2025 ($ MILLION)
FIGURE 68 GERIATRIC POPULATION IN JAPAN (65 YEARS AND ABOVE) 2014 & 2060
FIGURE 69 JAPAN OPHTHALMIC DRUGS & DEVICES MARKET 2017-2025 ($ MILLION)
FIGURE 70 SOUTH KOREA OPHTHALMIC DRUGS & DEVICES MARKET 2017-2025 ($ MILLION)
FIGURE 71 CAUSES OF BLINDNESS IN AUSTRALIA IN 2016
FIGURE 72 AUSTRALIA OPHTHALMIC DRUGS & DEVICES MARKET 2017-2025 ($ MILLION)
FIGURE 73 AGING POPULATION GROWTH RATE IN LATIN AMERICA 2000-2050
FIGURE 74 LATIN AMERICA OPHTHALMIC DRUGS AND DEVICES MARKET 2017-2025 ($ MILLION)
FIGURE 75 MIDDLE EAST AND AFRICA OPHTHALMIC DRUGS AND DEVICES MARKET 2017-2025 ($ MILLION)
FIGURE 76 GLOBAL OPHTHALMOLOGY DEVICE MARKET SHARE IN 2015
FIGURE 77 GLOBAL OPHTHALMOLOGY DRUGS MARKET SHARE IN 2015
FIGURE 1 KEY FINDINGS OF THE REPORT
FIGURE 2 GLOBAL GERIATRIC POPULATION (65+) 2015 & 2020 (MILLION)
FIGURE 3 PROJECTIONS FOR THE PROPORTION OF GLOBAL GERIATRIC (60+) POPULATION
FIGURE 4 WORLDWIDE PREVALENCE OF PRESBYOPIA (BILLION)
FIGURE 5 PREVALENCE OF GLAUCOMA AT GLOBAL LEVEL (MILLION)
FIGURE 6 GLOBAL HEALTHCARE EXPENDITURE (% OF GDP) 2012-2014
FIGURE 7 HEALTHCARE EXPENDITURE OF DEVELOPED ECONOMIES AS % OF THEIR GDP IN 2014
FIGURE 8 HEALTHCARE EXPENDITURE OF DEVELOPING ECONOMIES AS % OF THEIR GDP IN 2014
FIGURE 9 HEALTHCARE EXPENDITURE (AS % OF GDP) OF MAJOR APAC COUNTRIES IN 2014
FIGURE 10 GROWTH IN GERIATRIC POPULATION FROM 2010 TO 2015(%)
FIGURE 11 RISK ASSOCIATED WITH THE OCULAR DISEASES
FIGURE 12 CAUSES OF BLINDNESS WORLDWIDE
FIGURE 13 GLOBAL CATARACT SURGERY DEVICE MARKET 2017-2025 ($ MILLION)
FIGURE 14 GLOBAL GLAUCOMA SURGERY DEVICE MARKET 2017-2025 ($ MILLION)
FIGURE 15 GLOBAL REFRACTIVE SURGERY DEVICE MARKET 2017-2025 ($ MILLION)
FIGURE 16 GLOBAL VITREORETINAL SURGERY DEVICE MARKET 2017-2025 ($ MILLION)
FIGURE 17 GLOBAL CONTACT LENS MARKET 2017-2025 ($ MILLION)
FIGURE 18 CONTACT LENS USAGE AMONG VARIOUS AGE GROUPS IN THE U.S. 2015
FIGURE 19 GLOBAL SPECTACLES MARKET 2017-2025 ($ MILLION)
FIGURE 20 EYE EXAMS IN THE U.S. ADULTS 2012-2014 (MILLION)
FIGURE 21 CONSUMPTION OF DRUGS BY TYPES IN 2016
FIGURE 22 GLOBAL EYE DROPS MARKET 2017-2025 ($ MILLION)
FIGURE 23 USAGE OF EYE DROPS AND EYE WASH IN U.S. HOUSEHOLDS 2012-2015 (%)
FIGURE 24 GLOBAL CAPSULES & TABLET MARKET 2017-2025 ($ MILLION)
FIGURE 25 GLOBAL EYE OINTMENT MARKET 2017-2025 ($ MILLION)
FIGURE 26 GLOBAL EYE GEL MARKET 2017-2025 ($ MILLION)
FIGURE 27 GLOBAL EYE SOLUTION MARKET 2017-2025 ($ MILLION)
FIGURE 28 GLOBAL GLAUCOMA DRUG MARKET 2017-2025 ($ MILLION)
FIGURE 29 DIFFERENT AGE GROUP WITH PROBABILITY OF BEING AFFECTED 2016
FIGURE 30 GLOBAL RETINAL DISORDER DRUGS MARKET 2017-2025 ($ MILLION)
FIGURE 31 GLOBAL DRY EYE DRUG MARKET 2017-2025($ MILLION)
FIGURE 32 GLOBAL ALLERGIC CONJUNCTIVITIS, INFLAMMATION AND CONJUNCTIVITIS DRUGS MARKET 2017-2025 ($ MILLION)
FIGURE 33 DIABETIC RETINOPATHY PREVALENCE IN THE U.S. 2011 & 2030 (MILLION)
FIGURE 34 TOTAL OPHTHALMIC CARE HOSPITAL IN US 2014
FIGURE 35 EYE DISEASES CASES ABOVE AGE OF 40 IN AMERICA 2014 (MILLION)
FIGURE 36 TOTAL VISUAL IMPAIRMENT AND BLINDNESS CASES ABOVE AGE 40 IN US IN 2014 (MILLION)
FIGURE 37 CASES ABOVE 40 AGE IN AMERICA 2014 (MILLION)
FIGURE 38 VALUE CHAIN ANALYSIS: OPHTHALMIC DRUGS MARKET
FIGURE 39 VALUE CHAIN ANALYSIS OF OPHTHALMIC DEVICES MARKET
FIGURE 40 KEY BUYING CRITERIA
FIGURE 41 KEY BUYING CRITERIA IMPACT
FIGURE 42 TOP REVENUE GENERATING SEGMENTS 2017-2025 ($ MILLION)
FIGURE 43 BENEFITS SUPPORTING HIGHER CATARACT SURGERIES
FIGURE 44 MAJOR RESEARCH AND DEVELOPMENT AREAS IN PLASMA TECHNOLOGY IN OPHTHALMOLOGY
FIGURE 45 NUMBER OF CLINICS USING VR SYSTEMS IN VARIOUS GEOGRAPHIES
FIGURE 46 KEY MARKET FACTS
FIGURE 47 VISION SCREENING PERFORMED BY EACH GROUP OF PROVIDERS (IN %)
FIGURE 48 ATTRACTIVE INVESTMENT PROPOSITION BY SEGMENT 2016 ($ MILLION)
FIGURE 49 ATTRACTIVE INVESTMENT PROPOSITION BY GEOGRAPHY 2016 ($ MILLION)
FIGURE 50 UNITED STATES (U.S.) MARKET 2017-2025 ($ MILLION)
FIGURE 51 CAUSES OF VISUAL IMPAIRMENT IN THE U.S. 2016
FIGURE 52 PREVALENCE RATE OF RETINAL DISORDERS IN CANADA, 2016
FIGURE 53 FINANCIAL COST SHARE OF RETINA DISORDER TREATMENT IN CANADA
FIGURE 54 GERIATRIC POPULATION IN EUROPE (65 YEARS AND ABOVE)
FIGURE 55 OPTOMETRISTS AND OPTICIANS PERCENTAGE IN EUROPEAN COUNTRIES 2016
FIGURE 56 ESTIMATED NUMBER OF PEOPLE HAVING SIGHT LOSS IN UK (MILLION)
FIGURE 57 UK OPHTHALMIC DRUGS & DEVICES MARKET 2017-2025 ($ MILLION)
FIGURE 58 FRANCE OPHTHALMIC DRUGS & DEVICES MARKET 2017-2025 ($ MILLION)
FIGURE 59 NUMBER OF LASIK SURGERIES IN GERMANY 2012-2020 (1000’S)
FIGURE 60 GERMANY OPHTHALMIC DRUGS & DEVICES MARKET 2017-2025 ($ MILLION)
FIGURE 61 GERIATRIC POPULATION IN SPAIN 65 YEARS AND ABOVE (% OF POPULATION)
FIGURE 62 SPAIN OPHTHALMIC DRUGS & DEVICES MARKET 2017-2025 ($ MILLION)
FIGURE 63 ITALY OPHTHALMIC DRUGS & DEVICES MARKET 2017-2025 ($ MILLION)
FIGURE 64 REST OF EUROPE OPHTHALMIC DRUGS & DEVICES MARKET 2017-2025 ($ MILLION)
FIGURE 65 HEALTHCARE EXPENDITURE IN ASIA-PACIFIC COUNTRIES
FIGURE 66 INDIA OPHTHALMIC DRUGS & DEVICES MARKET 2017-2025 ($ MILLION)
FIGURE 67 CHINA OPHTHALMIC DRUGS & DEVICES MARKET 2017-2025 ($ MILLION)
FIGURE 68 GERIATRIC POPULATION IN JAPAN (65 YEARS AND ABOVE) 2014 & 2060
FIGURE 69 JAPAN OPHTHALMIC DRUGS & DEVICES MARKET 2017-2025 ($ MILLION)
FIGURE 70 SOUTH KOREA OPHTHALMIC DRUGS & DEVICES MARKET 2017-2025 ($ MILLION)
FIGURE 71 CAUSES OF BLINDNESS IN AUSTRALIA IN 2016
FIGURE 72 AUSTRALIA OPHTHALMIC DRUGS & DEVICES MARKET 2017-2025 ($ MILLION)
FIGURE 73 AGING POPULATION GROWTH RATE IN LATIN AMERICA 2000-2050
FIGURE 74 LATIN AMERICA OPHTHALMIC DRUGS AND DEVICES MARKET 2017-2025 ($ MILLION)
FIGURE 75 MIDDLE EAST AND AFRICA OPHTHALMIC DRUGS AND DEVICES MARKET 2017-2025 ($ MILLION)
FIGURE 76 GLOBAL OPHTHALMOLOGY DEVICE MARKET SHARE IN 2015
FIGURE 77 GLOBAL OPHTHALMOLOGY DRUGS MARKET SHARE IN 2015
